Brian Wiley
Corporate Officer/Principal chez PORTAGE BIOTECH INC.
Fortune : - $ au 30/04/2024
Profil
Brian Wiley is the founder of Boston Bioconsulting LLC, which was founded in 2018.
He held the title of Principal at the company.
Currently, Mr. Wiley is the Chief Business Officer at Portage Biotech, Inc. since 2022 and the Senior VP-Corporate Development & Strategy at Aprea Therapeutics, Inc. since 2023.
In his former positions, Mr. Wiley worked as a Senior Director-Oncology Marketing at Celgene Corp., Director-Market Planning at Millennium Pharmaceuticals, Inc., Senior Director-Marketing & Business Development at Gloucester Pharmaceuticals, Inc., and Chief Commercial Officer at NewLink Genetics Corp.
from 2016 to 2018.
He also worked as a Senior Manager at Aventis Pharmaceuticals, Inc. from 1992 to 2004.
Mr. Wiley completed his undergraduate degree at The Pennsylvania State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PORTAGE BIOTECH INC
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Brian Wiley
| Sociétés | Poste | Début |
|---|---|---|
| PORTAGE BIOTECH INC. | Corporate Officer/Principal | 15/02/2022 |
| APREA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2023 |
| Boston Bioconsulting LLC | Fondateur | 01/08/2018 |
Anciens postes connus de Brian Wiley
| Sociétés | Poste | Fin |
|---|---|---|
| LUMOS PHARMA, INC. | Corporate Officer/Principal | 27/07/2018 |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Sales & Marketing | 26/04/2011 |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 01/01/2004 |
| CELGENE | Sales & Marketing | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Sales & Marketing | - |
Formation de Brian Wiley
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PORTAGE BIOTECH INC. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
| Boston Bioconsulting LLC |
